查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生物製劑合約製造市場 - 按提供的服務類型、按製造的生物製劑類型、按使用的表達系統類型、按業務規模、按公司規模、按關鍵地區：行業趨勢和全球預測（2022-2035）
市場調查報告書
商品編碼
1398313

全球生物製劑合約製造市場 - 按提供的服務類型、按製造的生物製劑類型、按使用的表達系統類型、按業務規模、按公司規模、按關鍵地區：行業趨勢和全球預測（2022-2035）

Biologics Contract Manufacturing Market by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions : Industry Trends and Global Forecasts, 2022 - 2035
出版日期: | 出版商: Roots Analysis | 英文 799 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2023 年，全球生物製品合約製造市場價值為 190 億美元，在預測期內（2023-2035 年）複合年增長率為 9%。

生物製藥合約製造市場被認為是生物製藥 CMO（合約製造商）行業，已顯示出強勁的活力和快速擴張，許多企業實體投資於研發以開拓新的治療方法。 這些創新包括抗體藥物偶聯物、生物相似藥以及細胞和基因療法。 多年來，全球這個快速成長的市場中已經出現了 250 多種生物療法和疫苗。 值得注意的是，生物製劑比傳統小分子藥物具有更高的成功率，因為它們的脫靶毒性較小，這是小分子藥物開發的重大挫折。

隨著人們對生物製劑的興趣增加，製藥業的投資已從小分子藥物明顯轉向生物製劑。 這一轉變，加上持續的科學進步和 FDA 批准的生物製劑的激增，預示著生物製劑時代的開始。 生物製藥有望從根本上塑造製藥業，並成為傳統醫學不可或缺的一部分。

這些服務提供者提供全面的解決方案，包括生物製程開發和優化、加快工作進度並降低與製造複雜生物製劑相關的高昂成本。這就是我的目標。 一些製造商可能會外包某些任務，以利用最先進的設備和專業知識。 尤其是當合約製造商採用軟體驅動的機器人等尖端技術來增強製造流程並降低與體力勞動相關的風險時。 隨著外包作為該領域可行且利潤豐厚的商業模式變得流行，全球生物製品合約製造市場預計將在預測期內顯著增長。

本報告分析了全球生物製品合約製造市場，概述了技術和服務、生產的生物製品類型、總體市場規模趨勢預測、按細分市場和地區劃分的詳細趨勢、資本交易和業務趨勢近期市場的聯盟情況，以及主要BCMO（生物製藥CMO）概述。

市場主要參與者

  • AGC Biologics
  • Boehringer Ingelheim
  • Catalent
  • Cell Therapies
  • Charles River Laboratories
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Kemwell Biopharma
  • Lonza
  • Miltenyi Biotec
  • Minaris Regenerative Medicine
  • Samsung Biologics
  • Sandoz
  • Vetter Pharma
  • Wuxi Biologics

目錄

第一章簡介

第二章分析方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

  • 分析概述
  • 生物製藥概述
  • 生物製藥表達系統
  • 生物製藥製造工藝
  • 合約製造概要
  • 需要外包生物製藥製造業務
  • 選擇合約製造夥伴時的主要考量因素
  • 未來前景

第六章市場狀況

  • 分析概述
  • 生物製藥合約製造商：整體市場情勢

第七章分地區產能分析

  • 分析概述
  • 關鍵先決條件與參數
  • 生物製藥合約生產設施概覽
  • 按地區劃分的產能分析：北美生物製藥合約生產設施
  • 按地區劃分的產能分析：歐洲生物製藥合約生產設施
  • 按地區劃分的產能分析：亞太地區生物製藥合約生產設施
  • 按地區劃分的產能分析：世界其他地區的生物製藥合約生產設施

第 8 章北美生物製藥合約製造

  • 分析概述
  • 美國生物製藥合約製造：監管情景
  • 北美主要生物製藥 CMO
  • 北美其他主要生物製藥 CMO

第 9 章歐洲生物製藥合約製造

  • 分析概述
  • 歐洲生物製藥合約製造：監管情景
  • 歐洲領先的生物製藥 CMO
  • 歐洲其他主要生物製藥 CMO

第十章亞太及其他地區生物製藥合約生產

  • 分析概述
  • 中國的生物製藥合約製造
  • 中國主要生物製藥CMO
  • 印度的生物製藥合約製造
  • 印度領先的生物製藥 CMO
  • 日本的生物製藥合約製造
  • 日本主要生物製藥CMO
  • 韓國的生物製藥合約製造
  • 韓國主要生物製藥CMO
  • 澳洲的生物製藥合約製造
  • 澳洲領先的生物製藥 CMO
  • 亞太地區和世界其他地區 (ROW) 領先的生物製藥 CMO

第11章利基生物藥學領域

  • 分析概述
  • 雙特異性抗體
  • 抗體藥物偶聯物 (ADC)
  • 細胞療法
  • 基因治療
  • 病毒載體
  • 質粒 DNA

第 12 章案例研究：生物相似藥的合約生產

  • 分析概述
  • 生物相似藥概述
  • 生物相似藥開發階段
  • 生物相似藥許可的監管要求
  • 需要外包製造業務
  • 生物相似藥對全球合約製造市場的影響
  • 生物相似藥合約製造服務提供商
  • 與生物相似藥製造業務外包相關的問題

第13章案例研究：小分子藥物與高分子藥物/療法的比較

  • 分析概述
  • 小分子與大分子藥物/療法

第 14 章個案研究：內部生產

  • 分析概述
  • 內部生產
  • 生物製藥產業外包趨勢
  • 用於核准的生物製品的製造方法（2016-2022）
  • 選擇正確的策略：內部與外包

第 15 章 "自製還是外購：決策架構"

  • 分析概述
  • 關鍵先決條件與參數
  • 生物製藥合約製造商： "製造與採購" 決策
  • 結論

第十六章主要藥廠的舉措

  • 分析概述
  • 主要製藥公司的生物製藥相關舉措

第十七章商業夥伴/合作

  • 分析概述
  • 業務夥伴模式
  • 生物製藥的合約生產：商業聯盟/合作

第十八章企業併購（M&A）

  • 分析概述
  • 併購模式
  • 生物製藥合約生產：併購
  • 主要收購：交易倍數

第十九章近期擴充

  • 分析概述
  • 生物製藥合約製造：近期擴張

第 20 章近期趨勢

  • 分析概述
  • 資金類型
  • 生物製藥代工：融資與投資分析
  • 技術進步

第21章產能分析

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造：全球已安裝生產能力
  • 結論

第22章需求分析

  • 分析概述
  • 重要假設與分析方法
  • 世界對生物製藥的需求
  • 全球對新興新型生物製劑的需求

第 23 章生物製藥合約製造組織的總擁有成本

  • 分析概述
  • 主要參數
  • 假設和分析方法
  • 總擁有成本（範例資料集）
  • 中型生物製藥合約製造組織的總擁有成本（2000-2020 年）
  • 大型/超大型生物製藥合約製造組織的總擁有成本（2000-2020 年）

第24章全球生物製藥合約製造市場

  • 分析概述
  • 假設和分析方法
  • 全球生物製藥合約製造市場、過去趨勢（2018-2022 年）和預測（2023-2035 年）
  • 主要市場細分

第 25 章生物製藥合約製造市場：依提供的服務類型劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：依提供的服務類型劃分（2018 年、2023 年、2035 年）
  • 數據測量與驗證

第 26 章生物製藥合約製造市場：依生產的生物製品類型劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：依生產的生物製藥類型劃分（2018 年、2023 年、2035 年）
  • 數據測量與驗證

第 27 章生物製藥合約製造市場：依所用表達系統類型劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：依所用表達系統類型劃分（2018 年、2023 年、2035 年）
  • 數據測量與驗證

第 28 章生物製藥合約製造市場：依業務規模劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：依業務規模劃分（2018 年、2023 年、2035 年）
  • 數據測量與驗證

第 29 章生物製藥合約製造市場：依公司規模劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：依公司規模劃分（2018 年、2023 年、2035 年）
  • 數據測量與驗證

第 30 章生物製藥合約製造市場：按地區劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：按地區劃分（2018 年、2023 年、2035 年）
  • 數據測量與驗證

第 31 章生物製藥合約製造市場：按主要公司劃分

  • 分析概述
  • 重要假設與分析方法
  • 生物製藥合約製造市場：依主要公司劃分
  • 數據測量與驗證

第 32 章案例研究：虛擬製藥公司

  • 分析概述
  • 虛擬商業模式的歷史演變
  • 虛擬製藥公司是整個生物製藥產業的一部分
  • 將營運外包給虛擬服務供應商的優勢
  • 與將營運外包給虛擬服務提供者相關的主要挑戰

第33章SWOT分析

  • 分析概述
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • SWOT要素比較
  • 結論

第34章生物製藥CMO市場未來前景

  • 分析概述
  • 外包活動：未來幾年可望大幅成長
  • 從一次性合約過渡到策略夥伴關係
  • 整合/採用新的創新技術
  • 專注於利基治療領域
  • 不斷成長的生物相似藥市場有助於合約製造服務業的成長
  • 增強 CMO 職能，打造一站式服務
  • 旨在實現利潤最大化和擴展現有能力的離岸外包活動
  • 資金流入與外包預算增加
  • 贊助商和服務提供者面臨的挑戰
  • 結論

第35章結論

第36章管理分析

  • 分析概述
  • RoslinCT
  • JAFRAL Biosolutions
  • Discovery Life Sciences
  • Bioworkshops
  • Aldevron
  • Resilience
  • Minaris Regenerative Medicine
  • 53Biologics
  • Richter-Helm BioLogics

第 37 章附錄一：表格資料

第38章附錄二：公司與組織名單

第 39 章附錄 III：業務夥伴關係/合作詳情

簡介目錄
Product Code: RA100465

The global biologics contract manufacturing market is valued at USD 19 billion in 2023 growing at a CAGR of 9% during the forecast period 2023-2035.

The biologics contract manufacturing market, recognized as the biopharmaceutical CMO sector, demonstrates robust dynamism and rapid expansion, attracting numerous entities investing in research and development for pioneering new therapeutic modalities. These innovations encompass antibody drug conjugates, biosimilars, and cell and gene therapies. Over the years, this burgeoning market has seen the emergence of more than 250 biologic therapies and vaccines worldwide. Notably, biologics exhibit higher success rates compared to traditional small-molecule drugs due to their reduced off-target toxicity, a prevalent cause of setbacks in small molecule drug development.

The escalating interest in biologics has prompted a notable shift in investment within the pharmaceutical landscape, transitioning from small molecule drugs to biologics. This shift, coupled with continuous scientific advancements and the proliferation of FDA-approved biologics, heralds the dawn of the biologic's era. Biopharmaceuticals are anticipated to fundamentally shape the pharmaceutical industry, progressively becoming an indispensable component of conventional medical treatments.

These service providers offer comprehensive solutions encompassing bioprocess development and optimization, aiming to expedite operational timelines and mitigate the exorbitant costs associated with producing complex biologic drugs. Some manufacturers opt to outsource specific operations to leverage state-of-the-art facilities and expertise, especially when contract manufacturing firms employ cutting-edge technologies like software-driven robotics to enhance manufacturing processes and mitigate risks linked to manual methods. As outsourcing gains traction as a viable and advantageous business model within this sphere, the global market for biologics contract manufacturing is poised to witness remarkable growth in the forecast period.

Key Market Segments:

Type of Service Offered

  • API Manufacturing
  • FDF Manufacturing

Type of Biologic Manufactured

  • Antibodies
  • Cell Therapies
  • Vaccines
  • Other Biologics

Type of Expression System

  • Mammalian
  • Microbial
  • Others

Scale of Operation

  • Preclinical / Clinical
  • Commercial

Company Size

  • Small
  • Mid-sized
  • Large
  • Very Large

Key Geographical Region

  • North America
  • Europe
  • Asia
  • Latin America
  • Middle East and North Africa

Research Coverage:

  • The report studies the biologics contract manufacturing market based on type of services offered, type of biologic manufactured, type of expression system used, scale of operation, company size and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to five major regions
  • Executive summary of biologics contract manufacturing market key research insights on the current state and expected evolution of the biologics contract manufacturing market in the short to long term.
  • Introduction to biopharmaceuticals, manufacturing processes, expression systems used, and the significance of outsourcing in this industry.
  • Current market landscape of contract manufacturing companies analyzing companies offering biologics contract manufacturing services based on various parameters like services offered, biologic types, scale of operation, expression systems, and geographic locations.
  • Elaborated profiles of key contract manufacturing organizations in each region, highlighting their services, facilities, recent developments, and future outlook.
  • Case studies on biosimilars market examining opportunities for CMOs in the biosimilars market and comparing small and large molecule drug characteristics and manufacturing processes.
  • Big pharma manufacturing initiatives and collaborations reviewing initiatives by top pharma companies, collaborations, trends, and activities impacting biologics contract manufacturing.
  • Examining recent partnerships, mergers, acquisitions, and their impact on the biologics contract manufacturing industry.
  • Reviewing expansion initiatives, funding investments, and technological advancements in biomanufacturing.
  • Estimating manufacturing capacity and annual demand for top biologics based on patient population, dosing, and strength.
  • Analyzing the total cost of ownership for CMOs based on company size between 2023-2043.
  • Examining industry trends, drivers, challenges through a SWOT analysis and their relative impact on the biopharmaceutical industry.
  • Exploring the role of the virtual business model in biopharmaceuticals, its advantages, risks, and its impact on outsourcing operations.
  • Discussing anticipated market growth, opportunities, and trends expected to influence the biologics contract manufacturing industry in the forecast period.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on biologics contract manufacturing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • AGC Biologics
  • Boehringer Ingelheim
  • Catalent
  • Cell Therapies
  • Charles River Laboratories
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Kemwell Biopharma
  • Lonza
  • Miltenyi Biotec
  • Minaris Regenerative Medicine
  • Samsung Biologics
  • Sandoz
  • Vetter Pharma
  • Wuxi Biologics

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Biopharmaceutical Contract Manufacturing Market Overview
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Biopharmaceuticals
  • 5.3. Expression Systems for Biopharmaceuticals
    • 5.3.1. Insect Expression Systems
    • 5.3.2. Mammalian Expression Systems
    • 5.3.3. Microbial Expression Systems
      • 5.3.3.1. Bacterial Expression Systems
      • 5.3.3.2. Fungal Expression Systems
      • 5.3.3.3. Yeast Expression Systems
    • 5.3.4. Plant Expression Systems
    • 5.3.5. Mammalian versus Microbial Expression Systems
  • 5.4. Manufacturing Process of Biopharmaceuticals
    • 5.4.1. Upstream Processing
    • 5.4.2. Fermentation
    • 5.4.3. Downstream Processing
  • 5.5. Overview of Contract Manufacturing
  • 5.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
    • 5.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
    • 5.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
    • 5.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
  • 5.7. Key Considerations While Selecting a Contract Manufacturing Partner
  • 5.8. Future Perspectives

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Type of Service Offered
    • 6.2.5. Analysis by Type of Biologic Manufactured
    • 6.2.6. Analysis by Scale of Operation
    • 6.2.7. Analysis by Type of Expression System Used
    • 6.2.8. Analysis by Type of Bioreactor Used
    • 6.2.9. Analysis by Mode of Operation of Bioreactor

7. REGIONAL CAPABILITY ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Key Assumptions and Parameter
  • 7.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
    • 7.3.1. Analysis by Type of Service Offered
    • 7.3.2. Analysis by Scale of Operation
  • 7.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
  • 7.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
  • 7.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
  • 7.7. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

  • 8.1. Chapter Overview
  • 8.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
  • 8.3. Leading Biopharmaceutical CMOs in North America
    • 8.3.1. AGC Biologics
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Service Portfolio
        • 8.3.1.2.1. Process Development
        • 8.3.1.2.2. cGMP Manufacturing
        • 8.3.1.2.3. Quality and Regulatory Services
        • 8.3.1.2.4. Process Validation
      • 8.3.1.3. Financial Information
      • 8.3.1.4. Manufacturing Facilities
      • 8.3.1.5. Recent Developments and Future Outlook
    • 8.3.2. Catalent
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Service Portfolio
        • 8.3.2.2.1. Cell Line Development
        • 8.3.2.2.2. Biomanufacturing
        • 8.3.2.2.3. ADCs and Bioconjugates Manufacturing
        • 8.3.2.2.4. Biosimilars Development and Manufacturing
        • 8.3.2.2.5. Fill / Finish Solutions and Delivery Services
        • 8.3.2.2.6. Analytical Services
      • 8.3.2.3. Clinical Supply Services
      • 8.3.2.4. Financial Information
      • 8.3.2.5. Manufacturing Facilities
      • 8.3.2.6. Recent Developments and Future Outlook
    • 8.3.3. FUJIFILM Diosynth Biotechnologies
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Service Portfolio
        • 8.3.3.2.1. Strain Development
        • 8.3.3.2.2. Process Development
        • 8.3.3.2.3. cGMP Manufacturing
        • 8.3.3.2.4. Analytical Solutions
      • 8.3.3.3. Financial Information
      • 8.3.3.4. Manufacturing Facilities
      • 8.3.3.5. Recent Developments and Future Outlook
    • 8.3.4. KBI Biopharma
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Service Portfolio
        • 8.3.4.2.1. Process Development
        • 8.3.4.2.2. Analytical Development
        • 8.3.4.2.3. GMP Manufacturing
        • 8.3.4.2.4. Clinical Cell Therapy Support
      • 8.3.4.3. Manufacturing Facilities
      • 8.3.4.4. Recent Developments and Future Outlook
    • 8.3.5. Charles River Laboratories
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Service Portfolio
        • 8.3.5.2.1. Cell Sourcing
        • 8.3.5.2.2. Cell and Gene Therapy Solutions
        • 8.3.5.2.3. Biologics Testing Solutions
        • 8.3.5.2.4. Avian Vaccine Services
        • 8.3.5.2.5. QC Microbial Solutions
        • 8.3.5.2.6. Scientific and Regulatory Advisory Services
      • 8.3.5.3. Financial Information
      • 8.3.5.4. Manufacturing Facilities
      • 8.3.5.5. Recent Developments and Future Outlook
  • 8.4. Other Leading Biopharmaceutical CMOs in North America
    • 8.4.1. Cytiva
      • 8.4.1.1. Company Overview
    • 8.4.2. Patheon
      • 8.4.2.1. Company Overview
    • 8.4.3. Piramal Pharma Solutions
      • 8.4.3.1. Company Overview

9. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

  • 9.1. Chapter Overview
  • 9.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
    • 9.2.1. EMA's cGMP Regulations
  • 9.3. Leading Biopharmaceutical CMOs in Europe
    • 9.3.1. Boehringer Ingelheim (BioXcellence)
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Service Portfolio
        • 9.3.1.2.1. Process Development
          • 9.3.1.2.1.1. Expression Systems
          • 9.3.1.2.1.2. Upstream Technology
          • 9.3.1.2.1.3. Downstream Technology
          • 9.3.1.2.1.4. Other Process Development Services
        • 9.3.1.2.2. Quality Assurance
        • 9.3.1.2.3. Fill / Finish Services
      • 9.3.1.3. Financial Information
      • 9.3.1.4. Manufacturing Facilities
      • 9.3.1.5. Recent Developments and Future Outlook
    • 9.3.2. Lonza
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Service Portfolio
      • 9.3.2.3. Manufacturing Services
      • 9.3.2.4. Financial Information
      • 9.3.2.5. Manufacturing Facilities
      • 9.3.2.6. Recent Developments and Future Outlook
    • 9.3.3. Sandoz
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Service Portfolio
      • 9.3.3.3. Financial Information
      • 9.3.3.4. Manufacturing Facilities
      • 9.3.3.5. Recent Developments and Future Outlook
    • 9.3.4. Vetter Pharma
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Service Portfolio
      • 9.3.4.3. Manufacturing Facilities
      • 9.3.4.4. Recent Developments and Future Outlook
    • 9.3.5. Miltenyi Biotec
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Service Portfolio
      • 9.3.5.3. Manufacturing Facilities
      • 9.3.5.4. Recent Developments and Future Outlook
  • 9.4. Other Leading Biopharmaceutical CMOs in Europe
    • 9.4.1. Novasep
      • 9.4.1.1. Company Overview
    • 9.4.2. Olon
      • 9.4.2.1. Company Overview
    • 9.4.3. Rentschler Biopharma
      • 9.4.3.1. Company Overview

10. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND REST OF THE WORLD

  • 10.1. Chapter Overview
  • 10.2. Biopharmaceutical Contract Manufacturing in China
    • 10.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
  • 10.3. Leading Biopharmaceutical CMOs in China
    • 10.3.1. WuXi Biologics
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Service Portfolio
        • 10.3.1.2.1. Discovery Services
        • 10.3.1.2.2. Development Services
        • 10.3.1.2.3. Testing Services
        • 10.3.1.2.4. Clinical Manufacturing Services
      • 10.3.1.3. Financial Information
      • 10.3.1.4. Manufacturing Facilities
      • 10.3.1.5. Recent Developments and Future Outlook
  • 10.4. Biopharmaceutical Contract Manufacturing in India
    • 10.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
  • 10.5. Leading Biopharmaceutical CMOs in India
    • 10.5.1. Kemwell Biopharma
      • 10.5.1.1. Company Overview
      • 10.5.1.2. Service Portfolio
        • 10.5.1.2.1. Development Services for Biopharmaceuticals
        • 10.5.1.2.2. Manufacturing Services for Biopharmaceuticals
      • 10.5.1.3. Manufacturing Facilities
      • 10.5.1.4. Recent Developments and Future Outlook
  • 10.6. Biopharmaceutical Contract Manufacturing in Japan
    • 10.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
  • 10.7. Leading Biopharmaceutical CMOs in Japan
    • 10.7.1. Minaris Regenerative Medicine
      • 10.7.1.1. Company Overview
      • 10.7.1.2. Service Portfolio
        • 10.7.1.2.1. Manufacturing Development Services
        • 10.7.1.2.2. GMP Manufacturing
      • 10.7.1.3. Manufacturing Facilities
      • 10.7.1.4. Recent Developments and Future Outlook
  • 10.8. Biopharmaceutical Contract Manufacturing in South Korea
    • 10.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
  • 10.9. Leading Biopharmaceutical CMOs in South Korea
    • 10.9.2. Samsung Biologics
      • 10.9.2.1. Company Overview
      • 10.9.2.2. Service Portfolio
        • 10.9.2.2.1. Process Development
        • 10.9.2.2.2. Analytical Services
        • 10.9.2.2.3. cGMP Manufacturing Services
        • 10.9.2.2.4. Aseptic Fill / Finish Services
        • 10.9.2.2.5. Quality Services
      • 10.9.2.3. Financial Information
      • 10.9.2.4. Manufacturing Facilities
      • 10.9.2.5. Recent Developments and Future Outlook
  • 10.10. Biopharmaceutical Contract Manufacturing in Australia
    • 10.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
  • 10.11. Leading Biopharmaceutical CMOs in Australia
    • 10.11.1. Cell Therapies
      • 10.11.1.1. Company Overview
      • 10.11.1.2. Service Portfolio
      • 10.11.1.3. Manufacturing Facilities
      • 10.11.1.4. Recent Developments and Future Outlook
  • 10.12. Other Leading Biopharmaceutical CMOs in Asia-Pacific and Rest of the World
    • 10.12.1. AcuraBio (Formerly Known as Luina Bio)
      • 10.12.1.1. Company Overview
    • 10.12.2. Celltrion
      • 10.12.2.1. Company Overview
    • 10.12.3. Takara Bio
      • 10.12.3.1. Company Overview

11. NICHE BIOPHARMACEUTICAL SECTORS

  • 11.1. Chapter Overview
  • 11.2. Bispecific Antibodies
    • 11.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
    • 11.2.2. Bispecific Antibodies: Pipeline Analysis
      • 11.2.2.1. Analysis by Phase of Development
      • 11.2.2.2. Analysis by Target Indication
    • 11.2.3. Bispecific Antibody Therapeutics: Technology Platforms
    • 11.2.4. Key Considerations for Manufacturing and Associated Challenges
    • 11.2.5. Role of CMOs in Offering Services for Bispecific Antibodies
      • 11.2.5.1. CMOs Offering Services for Bispecific Antibodies
  • 11.3. Antibody Drug Conjugates (ADCs)
    • 11.3.1. Components of ADCs
      • 11.3.1.1. Antibody
      • 11.3.1.2. Cytotoxin
      • 11.3.1.3. Linker
    • 11.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
      • 11.3.2.1. Analysis by Status of Development
      • 11.3.2.2. Analysis by Target Disease Indication
      • 11.3.2.3. Most Active Players: Analysis by Number of Therapies
    • 11.3.3. Antibody Drug Conjugate Developers
    • 11.3.4. Manufacturing Process
  • 11.4. Cell Therapies
    • 11.4.5. Technical Challenges Related to Antibody Drug Conjugates Manufacturing
    • 11.4.6. Role of CMOs in Offering Services for ADCs
      • 11.4.6.1. CMOs Offering Services for ADCs
    • 11.4.1. Cell Therapies: Overall Market Landscape
    • 11.4.2. Overview of Cell Therapy Manufacturing
      • 11.4.2.1. Cell Therapy Manufacturing Models
        • 11.4.2.1.1. Centralized Manufacturing
        • 11.4.2.1.2. Decentralized Manufacturing
    • 11.4.3. Key Challenges for Manufacturing Cell Therapies
    • 11.4.4. Key Factors Impacting Cell Therapy Manufacturing
      • 11.4.4.1. Characterization
      • 11.4.4.2. Cost of Goods
      • 11.4.4.3. Automation of Cell Therapy Manufacturing
    • 11.4.5. Cell Therapies: Pipeline Analysis
      • 11.4.5.1. Analysis by Type of Cell Manufactured
    • 11.4.6. Stem Cell Therapies: Analysis by Phase of Development
    • 11.4.7. T-Cell Therapies: Analysis by Phase of Development
    • 11.4.8. Role of CMOs in Offering Services for Cell Therapies
      • 11.4.8.1. CMOs Offering Services for Cell Therapies
  • 11.5. Gene Therapies
    • 11.5.1. Gene Therapies: Pipeline Analysis
      • 11.5.1.1. Analysis by Stage of Development
      • 11.5.1.2. Analysis by Phase of Development
      • 11.5.1.3. Analysis by Type of Vector Used
        • 11.5.1.3.1. Clinical Pipeline
        • 11.5.1.3.2. Preclinical Pipeline
      • 11.5.1.4. Analysis by Therapeutic Area
        • 11.5.1.4.1. Clinical and Commercial Pipeline
        • 11.5.1.4.2. Preclinical Pipeline
    • 11.5.2. Role of CMOs in Offering Services for Gene Therapies
      • 11.5.2.1. CMOs Offering Services for Gene Therapies
  • 11.6. Viral Vectors
    • 11.6.1. Viral Vectors: Pipeline Analysis
      • 11.6.1.1. Analysis by Location of Viral Vectors Manufacturing Facilities
      • 11.6.1.2. Analysis by Type of Viral Vector Manufactured
    • 11.6.2. Role of CMOs in Offering Services for Viral Vectors
      • 11.6.2.1. CMOs Offering Services for Viral Vectors
  • 11.7. Plasmid DNA
    • 11.7.1. Plasmid DNA: Pipeline Analysis
      • 11.7.1.1. Analysis by Location of Manufacturing Facilities
    • 11.7.2. Role of CMOs in Offering Services for Plasmid DNA
      • 11.7.2.1. CMOs Offering Services for Plasmid DNA

12. CASE STUDY: OUTSOURCING OF BIOSIMILARS

  • 12.1. Chapter Overview
  • 12.2. Overview of Biosimilars
  • 12.3. Development Stages of Biosimilars
  • 12.4. Regulatory Requirements for Licensing of Biosimilars
  • 12.5. Need for Outsourcing Manufacturing Operations
  • 12.6. Impact of Biosimilars on the Global Contract Manufacturing Market
    • 12.6.1. Biosimilars: Historical Trend of FDA Approvals
  • 12.7. Biosimilars Contract Manufacturing Service Providers
  • 12.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

13. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

  • 13.1. Chapter Overview
  • 13.2. Small Molecule and Large Molecule Drugs / Therapies
    • 13.2.1. Comparison of General Characteristics
    • 13.2.2. Comparison of Key Specifications
    • 13.2.3. Comparison of Manufacturing Process
    • 13.2.4. Comparison of Key Manufacturing Challenges

14. CASE STUDY: IN-HOUSE MANUFACTURING

  • 14.1. Chapter Overview
  • 14.2. In-House Manufacturing
    • 14.2.1. Benefits Associated with In-House Manufacturing
    • 14.2.2. Risks Associated with In-House Manufacturing
  • 14.3. Outsourcing Trends in the Biopharmaceutical Industry
    • 14.3.1. Types of Outsourcing Partners
  • 14.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
  • 14.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

15. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Parameters
  • 15.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
    • 15.3.1. Scenario 1
    • 15.3.2. Scenario 2
    • 15.3.3. Scenario 3
    • 15.3.4. Scenario 4
  • 15.4. Conclusion

16. BIG PHARMA INITIATIVES

  • 16.1. Chapter Overview
  • 16.2. Biopharmaceutical Related Initiatives by Big Pharmaceutical Players
    • 16.2.1. Analysis by Number of Initiatives
    • 16.2.2. Analysis by Year of Initiative
    • 16.2.3. Analysis by Purpose of Initiative
    • 16.2.4. Analysis by Type of Initiative
      • 16.2.4.1. Analysis by Type of Partnership
      • 16.2.4.2. Analysis by Type of Expansion
    • 16.2.5. Analysis by Scale of Operation
    • 16.2.6. Analysis by Type of Biologic Manufactured
    • 16.2.7. Analysis of Big Pharma Players by Year of Initiative
    • 16.2.8. Analysis of Big Pharma Players by Purpose of Initiative
    • 16.2.9. Analysis by Year and Type of Initiative
    • 16.2.10. Analysis of Big Pharma Players by Region of Expansion
    • 16.2.11. Analysis of Big Pharma Players by Type of Biologic Manufactured

17. PARTNERSHIPS AND COLLABORATIONS

  • 17.1. Chapter Overview
  • 17.2. Partnership Models
  • 17.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
    • 17.3.1. Analysis by Year of Partnership
    • 17.3.2. Analysis by Type of Partnership
    • 17.3.3. Analysis by Year and Type of Partnership
    • 17.3.4. Analysis by Type of Biologic Manufactured
    • 17.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
    • 17.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
    • 17.3.7. Analysis by Scale of Operation
    • 17.3.8. Analysis by Therapeutic Area
    • 17.3.9. Most Active Players: Analysis by Number of Partnerships
    • 17.3.10. Analysis by Geography
      • 17.3.10.1. Local and International Agreements
      • 17.3.10.2. Intracontinental and Intercontinental Agreements

18. MERGERS AND ACQUISITIONS

  • 18.1. Chapter Overview
  • 18.2. Merger and Acquisition Models
  • 18.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
    • 18.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
    • 18.3.2. Analysis by Type of Acquisition
    • 18.3.3. Analysis by Geography
      • 18.3.3.1. Local and International Mergers and Acquisitions
      • 18.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
      • 18.3.3.3. Year-wise Trend in North America, Europe and Asia-Pacific
    • 18.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
    • 18.3.5. Analysis by Key Value Drivers
    • 18.3.6. Analysis by Year of Acquisition and Key Value Drivers
    • 18.3.7. Analysis by Type of Biologic Manufactured
    • 18.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
  • 18.4. Key Acquisitions: Deal Multiples
    • 18.4.1. Year-wise Trend of Deal Multiple Amount

19. RECENT EXPANSIONS

  • 19.1. Chapter Overview
  • 19.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
    • 19.2.1. Analysis by Year of Expansion
    • 19.2.2. Analysis by Purpose of Expansion
    • 19.2.3. Analysis by Year and Purpose of Expansion
    • 19.2.4. Analysis by Type of Biologic Manufactured
    • 19.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
    • 19.2.6. Analysis by Location of Expanded Facility
    • 19.2.7. Most Active Players: Analysis by Number of Recent Expansions
    • 19.2.8. Analysis by Purpose of Expansion and Location of Expanded Facility
    • 19.2.9. Analysis by Amount Invested
    • 19.2.10. Recent Expansions: 2016-2020 and 2021-2023 Scenario

20. RECENT DEVELOPMENTS

  • 20.1. Chapter Overview
  • 20.2. Types of Funding
  • 20.3. Biopharmaceutical Contract Manufacturing: Funding and Investment Analysis
    • 20.3.1. Analysis by Year of Funding
    • 20.3.2. Analysis by Amount Invested
    • 20.3.3. Analysis by Type of Funding
    • 20.3.4. Analysis by Year and Type of Funding
    • 20.3.5. Analysis of Funding Instances and Amount Invested by Geography (Continent)
    • 20.3.6. Analysis of Funding Instances and Amount Invested by Geography (Country)
    • 20.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 20.3.8. Most Active Players: Analysis by Total Amount Raised
    • 20.3.9. Leading Investors: Analysis by Number of Funding Instances
    • 20.3.10. Leading Investors: Analysis by Total Amount Raised
  • 20.4. Technological Advancements
    • 20.4.1. Single-Use Technology
    • 20.4.2. Process Analytical Technology (PAT)
    • 20.4.3. Continuous Processing
    • 20.4.4. Quality by Design (QbD) in Bio-processing
    • 20.4.5. Modular / Podular Biopharma Facilities

21. CAPACITY ANALYSIS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Biopharmaceutical Contract Manufacturing: Global Installed Capacity
    • 21.3.1. Analysis by Company Size
    • 21.3.2. Analysis by Type of Expression System Used
    • 21.3.3. Analysis by Geography
      • 21.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
      • 21.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
      • 21.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
      • 21.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
  • 21.4. Concluding Remarks

22. DEMAND ANALYSIS

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Global Demand for Biopharmaceuticals
  • 22.4. Global Demand for Emerging Novel Biologics
    • 22.4.1. Global Demand for ADC Therapeutics
    • 22.4.2. Global Demand for Cell Therapy Manufacturing

23. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS

  • 23.1. Chapter Overview
  • 23.2. Key Parameters
  • 23.3. Assumptions and Methodology
  • 23.4. Total Cost of Ownership (Sample Dataset)
  • 23.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
    • 23.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
    • 23.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20
  • 23.7. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
    • 23.7.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
    • 23.7.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET

  • 24.1. Chapter Overview
  • 24.2. Assumptions and Methodology
  • 24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.1. Scenario Analysis
      • 24.3.1.1. Conservative Scenario
      • 24.3.1.2. Optimistic Scenario
  • 24.4. Key Market Segmentations

25. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035
    • 25.3.1. API Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.2. FDF Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 25.4. Data Triangulation and Validation

26. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

  • 26.1. Chapter Overview
  • 26.2. Key Assumptions and Methodology
  • 26.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035
    • 26.3.1. Antibodies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 26.3.2. Cell Therapies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 26.3.3. Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 26.3.4. Other Biologics: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 26.4. Data Triangulation and Validation

27. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

  • 27.1. Chapter Overview
  • 27.2. Key Assumptions and Methodology
  • 27.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035
    • 27.3.1. Mammalian Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 27.3.2. Microbial Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 27.3.3. Other Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 27.4. Data Triangulation and Validation

28. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 28.1. Chapter Overview
  • 28.2. Key Assumptions and Methodology
  • 28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
    • 28.3.1. Preclinical / Clinical Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 28.3.2. Commercial Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 28.4. Data Triangulation and Validation

29. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

  • 29.1. Chapter Overview
  • 29.2. Key Assumptions and Methodology
  • 29.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
    • 29.3.1. Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 29.3.2. Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 29.3.3. Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 29.4. Data Triangulation and Validation

30. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY

  • 30.1. Chapter Overview
  • 30.2. Key Assumptions and Methodology
  • 30.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
    • 30.3.1. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.1.1. US: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.1.2. Canada: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 30.3.2. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.2.1. Italy: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.2.2. Germany: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.2.3. France: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.2.4. Spain: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.2.5. UK: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.2.6. Rest of Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 30.3.3. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.3.1. China: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.3.2. India: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.3.3. South Korea: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.3.4. Japan: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
      • 30.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 30.3.4. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 30.3.5. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 30.8. Data Triangulation and Validation

31. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS

  • 31.1. Chapter Overview
  • 31.2. Key Assumptions and Methodology
  • 31.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players
  • 31.4. Data Triangulation and Validation

32. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES

  • 32.1. Chapter Overview
  • 32.2. Historical Evolution of the Virtual Business Model
  • 32.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
  • 32.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
  • 32.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers

33. SWOT ANALYSIS

  • 33.1. Chapter Overview
  • 33.2. Strengths
  • 33.3. Weaknesses
  • 33.4. Opportunities
  • 33.5. Threats
  • 33.6. Comparison of SWOT Factors
  • 33.7. Conclusion

34. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

  • 34.1. Chapter Overview
  • 34.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
  • 34.3. Shift from One-time Contracts to Strategic Partnerships
  • 34.4. Integration / Adoption of New and Innovative Technologies
    • 34.4.1. Single-use Bioreactors
    • 34.4.2. Novel Bioprocess Techniques
    • 34.4.3. Bioprocess Automation
  • 34.5. Focus on Niche Therapeutic Areas
  • 34.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
  • 34.7. Capability Expansion by CMOs to become One-Stop-Shops
  • 34.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
  • 34.9. Increase in Financial Inflow and Outsourcing Budgets
  • 34.10. Challenges Faced by Sponsors and Service Providers
    • 34.10.1. Concerns Related to Single-use Systems
    • 34.10.2. Issues Related to Capacity Fluctuations
  • 34.11. Concluding Remarks

35. CONCLUSION

36. EXECUTIVE INSIGHTS

  • 36.1. Chapter Overview
  • 36.2. RoslinCT
    • 36.2.1. Company Snapshot
    • 36.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer
  • 36.3. Chapter Overview
  • 36.3. JAFRAL Biosolutions
    • 36.3.1. Company Snapshot
    • 36.3.2. Interview Transcript: Frenk Smrekar, Chief Executive Officer And Co-Founder
  • 36.4. Chapter Overview
  • 36.4. Discovery Life Sciences
    • 36.4.1. Company Snapshot
    • 36.4.2. Interview Transcript: Dominic Clarke, Chief Technical Officer, Cell And Gene Therapy
  • 36.5. Chapter Overview
  • 36.5. Bioworkshops
    • 36.5.1. Company Snapshot
    • 36.5.2. Interview Transcript: Nick Kotlarski, President and Chief Operating Officer
  • 36.6. Aldevron
    • 36.6.1. Company Snapshot
    • 36.6.2. Interview Transcript: Jeff Briganti, Senior Director Of Global Strategic Marketing
  • 36.7. Resilience
    • 36.7.1. Company Snapshot
    • 36.7.2. Interview Transcript: Tarek Abdel-Gawad, Senior Director of Commercial Strategy and Market Insights
  • 36.8. Minaris Regenerative Medicine
    • 36.8.1. Company Snapshot
    • 36.8.2. Interview Transcript: Luc St-Onge, Global Head of Sales and Marketing and Head of Business Development (Germany)
  • 36.9. 53Biologics
    • 36.9.1. Company Snapshot
    • 36.9.2. Interview Transcript: Francisco Manuel Reyes Sosa, Business Development Manager
  • 36.10. Richter-Helm BioLogics
    • 36.10.1. Company Snapshot
    • 36.10.2. Interview Transcript Antje Weingarth, Manager Marketing and Sales

37. APPENDIX I: TABULATED DATA

38. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

39. APPENDIX III: DETAILS OF PARTNERSHIPS AND COLLABORATIONS